🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Russian COVID-19 vaccine approval imminent, source says

Published 2020-07-29, 08:32 a/m
© Reuters. FILE PHOTO: Kirill Dmitriev, chief executive of the Russian Direct Investment Fund

By Andrew Osborn

MOSCOW (Reuters) - Russia's first potential COVID-19 vaccine will win local regulatory approval in the first half of August and be administered to frontline health workers soon afterwards, a development source close to the matter told Reuters.

A state research facility in Moscow - the Gamaleya Institute - completed early human trials of the adenovirus-based vaccine this month and expects to begin large-scale trials in August.

The vaccine will win regulatory approval from authorities in Russia while that large-scale trial continues, the source said, highlighting Moscow's determination to be the first country in the world to approve a vaccine.

The speed at which Russia is moving to roll out the vaccine has prompted some Western media to question whether Moscow is putting national prestige before solid science and safety.

"(Regulatory) approval will be in the first two weeks of August," the development source said. "August 10 is the expected date, but it will definitely be before August 15. All (trial) results so far are highly positive."

The source added that Russian health workers treating COVID-19 patients will be offered the chance of volunteering to be vaccinated soon after the vaccine receives the regulatory approval.

Separately, Russia's Interfax news agency cited "an informed source" as saying the vaccine would be registered from Aug. 10-12 and be administered from Aug. 15 onwards.

The press service of the Russian Direct Investment Fund (RDIF), which is coordinating and funding Russia's vaccine development efforts, declined to comment, but its head, Kirill Dmitriev, has denied that Russia's vaccine push is compromising safety.

"The Ministry of Health in Russia is following all necessary strict procedures. No corners are being cut," Dmitriev said on Tuesday.

Dmitriev likened what he said was Russia's success in developing a vaccine to the Soviet Union's 1957 launch of Sputnik 1, the world's first satellite.

"Just as Sputnik was the result of very talented Russian scientists ... our vaccine research is based on the work of great Russian scientists," he said.

Britain's National Cyber Security Centre said this month that hackers backed by the Russian state were trying to steal COVID-19 vaccine and treatment research from academic and pharmaceutical institutions around the world. The allegations have been denied by Moscow.

© Reuters. FILE PHOTO: Kirill Dmitriev, chief executive of the Russian Direct Investment Fund

More than 100 possible vaccines are being developed around the world to try to stop the COVID-19 pandemic. At least four are in final Phase III human trials, according to WHO data, including three developed in China and another in Britain.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.